Dear Investors, This is John Rim, CEO of Samsung Biologics. We sincerely appreciate your continued faith and trust in Samsung Biologics.

삼성바이오로직스는 반기 별도 기준 최초로 매출 1조원을 달성했습니다. 오늘 삼성바이오로직스는 2분기 실적을 발표했습니다. 지난 1분기에는 2공장 Slowdown이 있었지만, 2분기에는 전 공장이 안정적으로 가동됨에 따라 생산 및 매출증가로 이어져 상반기 매출 1조원이라는 성과를 이뤄낼 수 있었습니다. 당사는 지난 4월, 유상증자를 성공적으로 마무리한 데 이어 삼성바이오에피스 지분을 인수해 100% 자회사로 편입한 바 있습니다. 이번 실적 발표에는 바이오에피스의 실적도 반영되었으며, 2분기 연결기준 매출 6,514억원, 영업이익 1,697억원을 기록했습니다. 삼성바이오에피스는 우수한 바이오 제약 개발 역량을 기반으로, 더욱 신속하고 유연한 성장 전략을 추진해 포트폴리오 리더십을 지속적으로 확대해나갈 계획입니다. 바이오로직스의 제조 역량과 바이오에피스의 개발 역량이 더해져 더욱 시너지를 낼 수 있을 것으로 기대하고 있습니다.

I am very proud to announce that Samsung Biologics, independent of Bioepis, achieved revenues exceeding 1 trillion won for the first time on a half-year basis. This is mainly attributable to the stable manufacturing operations of all plants leading to increased revenue in spite of the scheduled slow-down for regular maintenance in Plant 2 in the 1st quarter. Furthermore, as a result of the acquisition of remaining stakes in Samsung Bioepis completed in April, Samsung Biologics benefitted from the effect from the consolidation of Samsung Bioepis' P/L as a wholly owned subsidiary. Accordingly, we posted a record 2nd quarter revenue of 651.4 billion won and operating profit of 169.7 billion won on a consolidated basis. Driven by our operational excellence and flawless quality and regulatory track record, we have been maintaining solid sales momentum with a robust cumulative backlog. We had already secured contract agreements for 7 products with 5 global biopharmaceutical companies for Plant 4, which is currently under construction and will come on line in October (to be fully GMP ready by mid-2023). At the same time, we are continuously negotiating with global big-pharmaceutical companies for additional pre-sales. Moreover, we signed a land purchase agreement with the Incheon Free Economic Zone (IFEZ) on July 18th to build out our second biocampus, dubbed “Bio Campus II”, to preemptively respond to the changes and needs of the market. Bio Campus II is designed to support Samsung Biologics' plans to establish a foundation for our future growth engine with large-scale manufacturing capacity for monoclonal antibodies, portfolio expansion, and an open innovation facility.

We are also pleased to inform you that we successfully completed the purchase of Biogen's stake in Samsung Bioepis and the rights issue in April. With excellence in biosimilars development capabilities, we expect to have our portfolio leadership expanded continuously by pursuing a more flexible and accelerated growth strategy. As an extension of our efforts for sustainable management that began in earnest in 2021, we published our second annual ESG report on July 11th to address a wide range of environmental, social, and governance (ESG) activities that had been carried out in the past year in addition to outlining our plans for the upcoming year. Under our mission of ‘Driven. For a Sustainable Life.', we are continuously improving and committing our resources to create a more sustainable environment, build a healthier society, and implement responsible business activities. We will be steadfastly committed to a wide range of socially and environmentally equitable practices to contribute to society with sustainable growth and development. With our pre-emptive and bold investments backed by solid business execution, Samsung Biologics will continue our path forward from the world's best contract development and manufacturing organization (CDMO) to a fully integrated global bio-pharmaceutical company. I would like to express my deepest gratitude for your consistent interest and trust in Samsung Biologics, and greatly appreciate your continued faith and encouragement to support the perpetual growth and sustainable development of all of our businesses.

As always, thank you for your support.

Sincerely, John Rim President & CEO, Samsung Biologics